Scientific Publications Search Search Author Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Daniel, Peter Prof. Dr. (1) Hinz, Michael Dr. (1) Keller, Ulrich Dr. med. (2) Lusatis, Simone (1) Mathas, Stephan Dr. (12) Na, Il-Kang Dr. (1) Pezzutto, Antonio Prof. Dr. (1) Scheidereit, Claus Prof. Dr. (1) Schmitt, Clemens Prof. Dr. (1) Wollert-Wulf, Brigitte (2) (-) Janz, Martin Dr. (10) 2003 (3) 2004 (2) 2005 (2) (-) 2006 (4) (-) 2007 (2) 2008 (2) 2009 (3) 2010 (1) 2011 (4) 2012 (2) 2013 (2) 2014 (1) 2015 (2) 2016 (1) 2017 (3) 2018 (1) 2019 (1) 2020 (4) 2021 (3) (-) 2022 (4) 2023 (6) 2024 (1) Advanced Light Microscopy (1) (-) Biology of Malignant Lymphomas (10) Cancer Genetics and Cellular Stress Responses (1) Cell Biology of Immunity (1) Computational Regulatory Genomics (1) Genetics and Genomics of Cardiovascular Diseases (1) Genome Diversification & Integrity (1) Immune Dysregulations in Oncology (1) Mechanism-based Cancer Therapies (2) Microenvironmental Regulation in Autoimmunity and Cancer (1) Mobile DNA (1) Myology (1) Proteome Dynamics (16) Proteomics (2) Proteomics and Metabolomics (1) RNA Biology and Posttranscriptional Regulation (3) Structural Biology of Membrane-Associated Processes (1) Translational Cardiology and Functional Genomics (1) 10 Results: Active Filter: Janz, Martin Dr.Biology of Malignant Lymphomas200620072022 Sort: Result score Newest to oldest Oldest to newest January 01, 2022 / Leuk Lymphoma Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals S. Denker A. Bittner M. Frick J. Kase J. Hoffmann C. Trenker U. Keller C. Bogner A. Hüttmann J. Dürig M. Janz S. Mathas R. Marks U. Krohn I.K. Na L. Bullinger C.A. Schmitt February 17, 2022 / N Engl J Med Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma M.R. Bishop M. Dickinson D. Purtill P. Barba A. Santoro N. Hamad K. Kato A. Sureda R. Greil C. Thieblemont F. Morschhauser M. Janz I. Flinn W. Rabitsch Y.L. Kwong M.J Kersten M.C. Minnema H. Holte E.H.L. Chan J. Martinez-Lopez A.M.S. Müller R.T. Maziarz J.P. McGuirk E. Bachy S. Le Gouill M. Dreyling H. Harigae D. Bond C. Andreadis P. McSweeney M. Kharfan-Dabaja S. Newsome E. Degtyarev R. Awasthi C. Del Corral G. Andreola A. Masood S.J. Schuster U. Jäger P. Borchmann J.R. Westin March 01, 2022 / Clin Neuroradiol Differentiation of cerebral neoplasms with vessel size imaging (VSI) A. Foda E. Kellner A. Gunawardana X. Gao M. Janz A. Kufner A.A. Khalil R. Geran R. Mekle J.B. Fiebach I. Galinovic April 01, 2022 / Acta Neurol Belg A peculiar case of primary central nervous system T-cell lymphoma with indolent behavior D. Wasilewski M. Janz A. Koch A. Rosenwald U. Keller P. Vajkoczy K. Faust I. Anagnostopoulos J. Radke March 15, 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou April 01, 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel February 01, 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken April 01, 2007 / Leukemia Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells M. Janz T. Stuehmer L.T. Vassilev R.C. Bargou May 01, 2007 / Br J Haematol Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis A. Lietz M. Janz M. Sigvardsson F. Jundt B. Doerken S. Mathas May 15, 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas
January 01, 2022 / Leuk Lymphoma Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals S. Denker A. Bittner M. Frick J. Kase J. Hoffmann C. Trenker U. Keller C. Bogner A. Hüttmann J. Dürig M. Janz S. Mathas R. Marks U. Krohn I.K. Na L. Bullinger C.A. Schmitt
February 17, 2022 / N Engl J Med Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma M.R. Bishop M. Dickinson D. Purtill P. Barba A. Santoro N. Hamad K. Kato A. Sureda R. Greil C. Thieblemont F. Morschhauser M. Janz I. Flinn W. Rabitsch Y.L. Kwong M.J Kersten M.C. Minnema H. Holte E.H.L. Chan J. Martinez-Lopez A.M.S. Müller R.T. Maziarz J.P. McGuirk E. Bachy S. Le Gouill M. Dreyling H. Harigae D. Bond C. Andreadis P. McSweeney M. Kharfan-Dabaja S. Newsome E. Degtyarev R. Awasthi C. Del Corral G. Andreola A. Masood S.J. Schuster U. Jäger P. Borchmann J.R. Westin
March 01, 2022 / Clin Neuroradiol Differentiation of cerebral neoplasms with vessel size imaging (VSI) A. Foda E. Kellner A. Gunawardana X. Gao M. Janz A. Kufner A.A. Khalil R. Geran R. Mekle J.B. Fiebach I. Galinovic
April 01, 2022 / Acta Neurol Belg A peculiar case of primary central nervous system T-cell lymphoma with indolent behavior D. Wasilewski M. Janz A. Koch A. Rosenwald U. Keller P. Vajkoczy K. Faust I. Anagnostopoulos J. Radke
March 15, 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
April 01, 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel
February 01, 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
April 01, 2007 / Leukemia Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells M. Janz T. Stuehmer L.T. Vassilev R.C. Bargou
May 01, 2007 / Br J Haematol Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis A. Lietz M. Janz M. Sigvardsson F. Jundt B. Doerken S. Mathas
May 15, 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas